Chimeric vaccine against tick-borne encephalitis virus
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsAlexander Pletnev, Ruhe Men, Robert Chanock, Ching-Juh Lai
Life of this patent
Estimating the term…
Abstract
A live, attenuated chimeric virus vaccine against tick-borne encephalitis virus comprising the preM and E structural genes of the tick-borne encephalitis Langat virus and the non-structural genes of the mosquito-borne dengue virus. The live chimeric vaccine was administered intraperitoneally and exhibited complete attenuation in mice while at the same time providing protection against subsequent challenge with the virulent parental Langat virus.
Claims10
A viable chimeric recombinant flavivirus, comprising:
- a first region of nucleic acid operably encoding preM and E structural proteins of a Langat virus operably linked to a second region of nucleic acid operably encoding non-structural proteins of a dengue 1 virus, dengue 2 virus, dengue 3 virus, or dengue 4 virus, wherein said Langat virus is defined as an attenuated tick-borne encephalitis virus.
A recombinant DNA construct comprising:
- a first region of nucleic acid operably encoding preM and E structural proteins of a Langat virus operably linked to a second region of nucleic acid operably encoding non-structural proteins of a dengue 1 virus, dengue 2 virus, dengue 3 virus, or dengue 4 virus incorporated within an expression vector, wherein said Langat virus is defined as an attenuated tick-borne encephalitis virus.
Dependencies are inferred from the claim text.